These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 28408804)

  • 1. Spotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy.
    Buchbinder D; Nugent D; Hsieh L
    Drug Des Devel Ther; 2017; 11():1055-1063. PubMed ID: 28408804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.
    Deuson R; Danese M; Mathias SD; Schoonen M; Fryzek J
    J Med Econ; 2012; 15(5):956-76. PubMed ID: 22533524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moving towards a new era in the management of chronic immune thrombocytopenia.
    Wadenvik H; Olsson B
    Ann Hematol; 2010 Jul; 89 Suppl 1():87-93. PubMed ID: 20339846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia.
    Kuter DJ; Tarantino MD; Lawrence T
    Blood Rev; 2021 Sep; 49():100811. PubMed ID: 33781612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of Romiplostim Mechanism of Action and Clinical Applicability.
    Bussel JB; Soff G; Balduzzi A; Cooper N; Lawrence T; Semple JW
    Drug Des Devel Ther; 2021; 15():2243-2268. PubMed ID: 34079225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful early romiplostim use in a case of severe immune thrombocytopenia with critical carotid arterial injury.
    Watanabe R; Tabayashi T; Tomikawa T; Sagawa M; Anan-Nemoto T; Kimura Y; Takahashi Y; Tokuhira M; Otaki S; Oi H; Sawano M; Sugiyama S; Kizaki M
    Int J Hematol; 2017 Jan; 105(1):100-103. PubMed ID: 27709451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP).
    Klaassen RJ; Mathias SD; Buchanan G; Bussel J; Deuson R; Young NL; Collier A; Bomgaars L; Blanchette V
    Pediatr Blood Cancer; 2012 Mar; 58(3):395-8. PubMed ID: 21910213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children.
    Ramaswamy K; Hsieh L; Leven E; Thompson MV; Nugent D; Bussel JB
    J Pediatr; 2014 Sep; 165(3):600-5.e4. PubMed ID: 24857517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
    Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M
    J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
    Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
    Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Romiplostim on Health-Related Quality of Life in Children with Primary Immune Thrombocytopenia and Associated Burden in Their Parents.
    Mathias SD; Li X; Eisen M; Carpenter N; Crosby RD; Blanchette VS
    Pediatr Blood Cancer; 2016 Jul; 63(7):1232-7. PubMed ID: 27037553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside.
    Molineux G; Newland A
    Br J Haematol; 2010 Jul; 150(1):9-20. PubMed ID: 20298251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia.
    Mokhtar GM; Tantawy AA; El Sherif NH
    Platelets; 2012; 23(4):264-73. PubMed ID: 22471399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim.
    Kohn B; Bal G; Chirek A; Rehbein S; Salama A
    BMC Vet Res; 2016 Jun; 12():96. PubMed ID: 27283401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes.
    Grace RF; Shimano KA; Bhat R; Neunert C; Bussel JB; Klaassen RJ; Lambert MP; Rothman JA; Breakey VR; Hege K; Bennett CM; Rose MJ; Haley KM; Buchanan GR; Geddis A; Lorenzana A; Jeng M; Pastore YD; Crary SE; Neier M; Neufeld EJ; Neu N; Forbes PW; Despotovic JM
    Am J Hematol; 2019 Jul; 94(7):741-750. PubMed ID: 30945320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia.
    Michel M; Wasser J; Godeau B; Aledort L; Cooper N; Tomiyama Y; Khellaf M; Wang X
    Ann Hematol; 2015 Dec; 94(12):1973-80. PubMed ID: 26341755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnostic approach and treatment of immune thrombocytopenia in adults].
    Kolonić SO; Patekar MB; Milunović V
    Acta Med Croatica; 2013 Mar; 67(1):3-11. PubMed ID: 24279250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.